|
|
|
|
2seventy Bio Inc (NASDAQ: TSVT) |
|
Price: $5.0000
$0.01 
0.200%
|
| Day's High:
| $5.01
| Week Perf:
| 0.2 %
|
| Day's Low: |
$ 4.99 |
30 Day Perf: |
1.01 % |
| Volume (M): |
1,158,100 |
52 Wk High: |
$ 0.00 |
| Volume (M$): |
$ 5,791 |
52 Wk Avg: |
$0.00 |
| Open: |
$5.00 |
52 Wk Low: |
$0.00 |
|
|
| Market Capitalization (Millions $) |
267 |
| Shares
Outstanding (Millions) |
53 |
| Employees |
202 |
| Revenues (TTM) (Millions $) |
48 |
| Net Income (TTM) (Millions $) |
-4 |
| Cash Flow (TTM) (Millions $) |
45 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
2seventy Bio Inc is a biotechnology company that focuses on developing novel therapeutics for the treatment of various diseases. The company employs advanced genetic and protein engineering techniques to create innovative drug candidates. Their research and development efforts are primarily focused on oncology and rare diseases. 2seventy Bio Inc aims to provide targeted and effective treatments that address critical unmet medical needs.
Company Address: 60 Binney Street Cambridge 2142 MA
Company Phone Number: 675-7270 Stock Exchange / Ticker: NASDAQ TSVT
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Thu, Feb 6 2025 3:39 PM UTC
In a year marked by resilience and strategic refocusing, 2seventy bio, Inc. (Nasdaq: TSVT), has made significant strides in its efforts to establish a robust foothold within the biopharmaceutical industry. From achieving impressive sales results for its CAR-T therapy, Abecma, to the sale of its Hemophilia A candidate and gene editing technologies to Novo Nordisk, the company...
|
| Announcement
Published Wed, Oct 9 2024 8:00 PM UTC
: The biotechnology sector continues to be a dynamic and volatile industry, characterized by rapid advancements in research and development juxtaposed against rigorous regulatory scrutiny and volatile market behaviors. A pertinent example of these fluctuations is evident in the recent investigation launched by the law firm Bronstein, Gewirtz & Grossman, LLC into potential se...
|
| Announcement
Published Fri, Sep 27 2024 8:00 PM UTC
CSIMarket.com : Edition September 27, 2024 Investigation Launched into 2seventy bio, Inc.: Investors Urged to Collaborate NEW YORK The renowned legal establishment of Bronstein, Gewirtz, and Grossman, LLC, hath declared an undertaking of an inquiry concerning potential grievances associated with the acquisitions of securities from 2seventy bio, Inc. (henceforth referred...
|
| Business Update
Published Wed, Sep 25 2024 10:47 AM UTC
2seventy bio and Bristol Myers Squibb Discontinue Phase 3 KarMMa-9 Study Enrollment Amid Promising Q3 Financial Outlook CAMBRIDGE, Mass. - 2seventy bio, Inc. (Nasdaq: TSVT) recently announced a significant strategic development in collaboration with Bristol Myers Squibb (BMS). The two companies have decided to discontinue enrollment in the ongoing Phase 3 KarMMa-9 study, w...
|
| Business Update
Published Wed, Aug 7 2024 11:51 AM UTC
In a compelling display of corporate metamorphosis, 2seventy bio, Inc. (NASDAQ: TSVT) has unveiled its financial results for Q2 2024, which depict a rollercoaster journey marked by both extraordinary growth and the specter of short-term challenges. The biopharmaceutical company, based in Cambridge, Massachusetts, signaled its significant transformation under CEO Chip Baird, ...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-0.1 $ |
| Revenues (TTM) |
0.91 $
|
| Cash Flow (TTM) |
0.84 $ |
| Cash |
1.73 $
|
| Book Value |
4 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
239,431 |
| Net
Income per Employee (TTM) |
-20,257 |
| Receivable Turnover Ratio (TTM) |
2.68 |
| Inventory Turnover Ratio (TTM) |
- |
| Asset Turnover Ratio (TTM) |
0.14 |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.1 $
|
| Revenues (TTM) |
0.91 $ |
| Cash Flow (TTM) |
0.84 $ |
| Cash |
1.73 $
|
| Book Value |
4 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Ide Cel Commercial Activities Bristol-Myers Squibb |
|
 79.07 % |
of total Revenue |
| ABECMA Commercial Activities |
|
83.46 % |
of total Revenue |
| Bristol-Myers Squibb Outside of U S Ide-cel license and manufacturing services License and Manufacturing Services |
|
16.45 % |
of total Revenue |
| Reportable Segment |
|
100 % |
of total Revenue |
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
2.53% 